Lonza to make drug active for Aurinia | Chemical & Engineering News
Volume 95 Issue 2 | pp. 12-13 | Concentrates
Issue Date: January 9, 2017

Lonza to make drug active for Aurinia

Department: Business
Keywords: pharmaceutical chemicals, voclosporin, lupus nephritis, Lonza

Lonza has signed an agreement to manufacture voclosporin for use by the biotech firm Aurinia in a Phase III clinical trial of the drug as a lupus nephritis treatment. Lonza has an option to supply the compound for up to 20 years. Aurinia CEO Charles Rowland says his firm spent years working with Lonza to optimize the drug’s complex manufacturing process.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment